Commerzbank Ag Analysts Give Rhoen Klinikum AG (RHK) a €25.00 Price Target

Rhoen Klinikum AG (ETR:RHK) has been given a €25.00 ($29.41) price target by investment analysts at Commerzbank Ag in a report issued on Tuesday, July 25th. The firm currently has a “neutral” rating on the stock.

Other equities analysts also recently issued research reports about the company. Baader Bank set a €24.00 ($28.24) price objective on Rhoen Klinikum AG and gave the company a “neutral” rating in a research report on Thursday, June 8th. DZ Bank AG reaffirmed a “sell” rating on shares of Rhoen Klinikum AG in a research report on Monday, May 29th. Three equities research analysts have rated the stock with a sell rating and six have given a hold rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of €24.06 ($28.31).

Rhoen Klinikum AG (ETR:RHK) traded up 0.379% during mid-day trading on Tuesday, reaching €27.517. 150 shares of the company traded hands. The firm has a market capitalization of €1.84 billion and a P/E ratio of 429.953. Rhoen Klinikum AG has a 12-month low of €22.91 and a 12-month high of €27.52. The company’s 50 day moving average price is €26.17 and its 200 day moving average price is €25.89.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by BNB Daily and is owned by of BNB Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/rhoen-klinikum-ag-rhk-given-a-25-00-price-target-by-commerzbank-ag-analysts-updated-updated-updated.html.

Rhoen Klinikum AG Company Profile

Analyst Recommendations for Rhoen Klinikum AG (ETR:RHK)

Receive News & Ratings for Rhoen Klinikum AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply